Heart Health Worsened in Pts With Chronic Hypoparathyroidism
METHODOLOGY:
Researchers conducted this study by merging data from population-based registries in Sweden to assess the risk for cardiovascular diseases in patients with chronic hypoparathyroidism.
They included 1982 patients with chronic hypoparathyroidism (mean age, 54.7 years; 76.7% women) and matched them to 19,494 control individuals without the condition.
The median follow-up time was 9.09 years for patients with chronic hypoparathyroidism and 8.91 years for control individuals.
The outcome was the presence of at least one cardiovascular event such as acute myocardial infarction, atrial fibrillation/flutter, heart failure, valvular heart disease, peripheral artery disease, or stroke or transient ischaemic attack; fatal cardiovascular disease was defined as death from any cardiovascular causes.
TAKEAWAY:
Patients with chronic hypoparathyroidism showed higher risks for valvular heart disease (hazard ratio [HR], 2.08; 95% CI, 1.67-2.60), peripheral artery disease (HR, 1.78; 95% CI, 1.41-2.26), heart failure (HR, 1.66; 95% CI, 1.44-1.90), atrial fibrillation/flutter (HR, 1.58; 95% CI, 1.38-1.81), and acute myocardial infarction (HR, 1.31; 95% CI, 1.05-1.64) than control individuals.
The risk for fatal cardiovascular disease was 59% higher in patients with chronic hypoparathyroidism than in control individuals (HR, 1.59; 95% CI, 1.40-1.80).
Women with chronic hypoparathyroidism showed significantly higher risks for valvular heart disease, peripheral artery disease, heart failure, atrial fibrillation, myocardial infarction, and fatal cardiovascular disease than their matched control individuals; however, no significant differences in any cardiovascular outcomes were observed between men with chronic hypoparathyroidism and their matched control individuals.
The increased risk for cardiovascular diseases in patients with chronic hypoparathyroidism remained consistent, regardless of the surgical or non-surgical aetiology of chronic hypoparathyroidism.
IN PRACTICE:
"[The study] findings highlight the need for close monitoring and preventive management of cardiovascular risk factors, particularly in women," the authors wrote.
SOURCE:
This study was led by Sigridur Björnsdottir, MD, PhD, Karolinska Institutet, Stockholm, Sweden. It was published online on April 28, 2025, in The Journal of Clinical Endocrinology & Metabolism .
LIMITATIONS:
This study lacked data on biochemical measures, physical activity, height, body weight, and blood pressure and relied on chronic obstructive pulmonary disease as a proxy variable for heavy smoking. Information about dosages of active vitamin D, calcium, and levothyroxine was not available in the registries.
DISCLOSURES:
This study was supported by a research grant from the Swedish Research Council, Knut and Alice Wallenberg Foundation, Novo Nordisk Foundation, Torsten and Ragnar Söderberg's Foundations, and Kristian Gerhard Jebsen Foundation. Several authors reported serving as research investigators, members of the advisory board and steering committees, and consultants and receiving research grants, consultancy fees, and personal fees from various pharmaceutical companies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
14 hours ago
- Medscape
Home BP Readings Often Beat Office Measurements
This transcript has been edited for clarity. Do you trust home blood pressure monitoring? You should, especially if it's done correctly. In fact, for many patients, it gives better data than occasional in-office readings, especially if they have white coat hypertension or masked hypertension. Here's how I interpret these data. First, I always ask if the device is validated and used properly. Upper arm cuffs are preferred, not wrist cuffs. Make sure they're sitting quietly for 5 minutes, back is supported, feet are flat, and no caffeine, smoking, or exercise within 30 minutes of the measurement. Then I look at the pattern, not one-off values. I ask patients to check twice in the morning and twice in the evening for 5 or 7 days. That gives me about 20-28 readings, which is enough to assess the true averages. I'm aiming for a home blood pressure goal that is slightly lower than the threshold used in the office, per the guidelines. If the average is above that consistently and the technique is solid, then I consider adjusting the therapy for that particular patient. Also, don't ignore variability. Wide swings may suggest nonadherence, autonomic dysfunction, or even secondary hypertension. If numbers are too low, especially with symptoms, it may be time to reduce the medications. Bottom line, home blood pressure data are reliable when done right. It often gives us a more accurate picture of real-world control than those seen in the office, and it should be part of routine hypertension management.
Medscape
15 hours ago
- Medscape
Mindfulness Therapy Aids IBD Patients With Mental Distress
TOPLINE: Mindfulness-based cognitive therapy reduced psychological distress and improved well-being of patients with inflammatory bowel disease (IBD), and it may offer benefits for sleep quality and inflammation. METHODOLOGY: Even in remission, many patients with IBD experience anxiety, depression, fatigue, and poor sleep, which can lower their quality of life, undermine self-care, and drive up healthcare use. Researchers conducted this trial in the Netherlands between July 2021 and May 2022 to strengthen the evidence for the effectiveness of mindfulness-based cognitive therapy in reducing psychological distress in patients with IBD who had been in remission for at least 3 months and experienced at least mild levels of distress. They randomly assigned 142 patients (mean age, 48.6 years; 64.1% women) to receive either mindfulness therapy plus usual treatment (n = 70; intervention group) or only usual treatment (n = 72; control group); the follow-up period lasted 12 months. The mindfulness therapy program included eight weekly group sessions of 2.5 hours, 30-45 minutes of daily home practice, and a 6-hour silent retreat day between sessions six and seven. Usual treatment included pharmacologic and surgical disease control treatments and the prevention of complications. The primary outcome was psychological distress post-intervention (3 months from baseline), measured using the Hospital Anxiety and Depression Scale (HADS) total score. Secondary outcomes included well-being, sleep, self-compassion, mindfulness skills, and disease activity. TAKEAWAY: Patients in the intervention group vs the control group showed reduced psychological distress (Cohen d [d], -0.61) and an improvement in the HADS total score (unstandardized coefficient B, -3.4; P < .001) at 3 months from baseline. The HADS total scores remained lower in the intervention group vs the control group during the entire 12-month follow-up duration. Compared with patients in the control group, those in the intervention group showed improved well-being (d, 0.41) and increases in mindfulness skills (d, 0.46) and self-compassion (d, 0.42). Patients in the intervention group vs the control group had a reduced total sleep time (d, -0.67) but an increased proportion of deep sleep (d, 0.7). No between-group difference was observed in the occurrence of disease flares, but patients in the control group showed a significant reduction in fecal calprotectin levels, an indicator of intestinal inflammation compared with patients in the control group (d, -0.49). IN PRACTICE: 'Our results demonstrate that MBCT [mindfulness-based cognitive therapy] could be a valuable addition to the currently limited number of psychological treatment options for patients with IBD with psychological distress. The group format of MBCT allows for the simultaneous treatment of more patients, potentially making it more cost-effective than individual therapy. Additionally, group therapy provides opportunities for peer support,' the authors of the study wrote. SOURCE: This study, led by Milou M. ter Avest, MD, Department of Psychiatry, Centre for Mindfulness, Radboud University Medical Centre, Nijmegen, the Netherlands, was published online in Inflammatory Bowel Diseases. LIMITATIONS: This study was limited by its unblinded design, risking expectation bias in self-reports. Mindfulness teachers had varied competence levels, which may have introduced bias. The study did not assess sleep disorders such as obstructive sleep apnea, narcolepsy, or restless legs syndrome that may have affected the sleep metrics. Additionally, electroencephalography headbands were not available for all patients, and technical and self-application issues may have led to unusable nights and data loss. DISCLOSURES: This trial was supported by ZonMw (the Netherlands Organisation for Health Research and Development) and the MindMore Foundation. Two authors reported serving on the advisory boards of various pharmaceutical companies, and one of them also reported receiving a grant from Royal DSM. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
16 hours ago
- Medscape
Maternal T1D Raises Odds of Adverse Neonatal Outcomes
TOPLINE: In a nationwide study of over 1.4 million singleton births, neonates of mothers with type 1 diabetes (T1D) had substantially higher odds of stillbirth, congenital malformations, preterm birth, hypoglycaemia, and neonatal death. METHODOLOGY: Researchers in Sweden conducted a nationwide cohort study of 1,402,394 singleton births to compare adverse neonatal outcomes between infants born to mothers with and without T1D. Data of neonates delivered at 22 or more completed gestational weeks between 2010 and 2022 were retrieved from the national birth register. Maternal T1D diagnoses and neonatal complications were ascertained from antenatal records and diagnostic codes. TAKEAWAY: During the study period, 0.5% of women were diagnosed with T1D. Neonates born to mothers with T1D had higher odds of stillbirth (adjusted odds ratio [aOR], 2.54; 95% CI, 1.98-3.28) and congenital malformations (aOR, 1.66; 95% CI, 1.50-1.84). Women with T1D and underweight or obesity showed a significantly higher prevalence of congenital malformations than their normal-weight counterparts. Neonates of women with T1D were far more likely to born preterm (< 34 weeks of gestational age; aOR, 3.80), be large for gestational age (aOR, 22.0), develop hypoglycaemia (aOR, 45.85), and experience neonatal mortality (aOR, 4.1). IN PRACTICE: "Neonates born to mothers with type 1 diabetes faced higher risks compared to neonates born to mothers without type 1 diabetes, highlighting the need for a better understanding of the causation and how care can be improved for their mothers," the authors wrote. SOURCE: This study was led by Alexandra Goldberg, Karolinska Institutet Soder Hospital, Stockholm, Sweden. It was published online on July 15, 2025, in Acta Paediatrica. LIMITATIONS: The authors were unable to account for all potential diabetic complications and maternal postprandial glucose levels before and during pregnancy. This study included only pregnancies that have completed 22 or more gestational weeks, which may have introduced selection bias. The authors could not control for elective or missed abortions attributable to congenital malformations. DISCLOSURES: This study did not receive any specific funding. The authors declared having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
